Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,014.59 USD

1,014.59
797,508

-25.68 (-2.47%)

Updated Oct 3, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

    Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA

    Rigel Pharmaceuticals, Inc. (RIGL) announced that the FDA has accepted its new drug application (NDA) seeking approval for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia

      Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA

      Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.

        Merrimack Completes Enrollment in Phase II Study for MM-141

        Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.

          CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day

          CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day

            John Blank headshot

            A Lazy, Unfocused Summer Is Here: Global Week Ahead

            A lazy, unfocused summer is here. Yet that sentiment might be bullish stocks. No new news may be good news -- in this upward trending market -- driven by momentum, mostly.

              GlaxoSmithKline's Benlysta Positive in Continuation Trial

              GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).

                Pfizer & Lilly Get Fast Track Designation for Pain Candidate

                Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

                  Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley

                  Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley

                    GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up

                    GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.

                      5 Stocks with Solid Sales Growth Catching Eyeballs

                      Sales growth is an important indicator of a company's health and ability to sustain its business. It offers investors an insight into product demand and pricing power.

                        Lilly Plans New Outcomes Study to Expand Jardiance Label

                        Eli Lilly and Company (LLY) along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance (empagliflozin) for treatment of patients with chronic kidney disease.

                          J&J Announces EU Regulatory Approval for Actelion Deal

                          Johnson & Johnson (JNJ) has received a regulatory approval from the European Commission (EC), thus completing all necessary formalities to close the pending acquisition of Swiss biopharmaceutical company, Actelion Ltd.

                            Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies

                            Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.

                              Regeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue?

                              Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

                                AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.

                                  Acorda Presents Phase III Data on PD Candidate CVT-301

                                  Acorda Therapeutics, Inc. (ACOR) presented data from a phase III study SPAN-PD, evaluating its late stage candidate CVT-301 (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS).

                                    Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.

                                    Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).

                                      Amgen Files for Repatha in the U.S., EU for Expanded Use

                                      Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.

                                        Regeneron Announces Positive Data on Carcinoma Candidate

                                        Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

                                          John Blank headshot

                                          Don't Be Rip Van Winkle: Global Week Ahead

                                          Not much looks to influence the markets this week -- until Thursday, when UK elections, an ECB decision and ex-FBI Commissioner James Comey testifies. Don't sleep on these potentially major events regarding market activity.

                                            BioMarin's (BMRN) Brineura Approved by European Commission

                                            BioMarin Pharmaceutical Inc. (BMRN) announced that the European Commission has approved Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2).

                                              Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day

                                              Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day

                                                Teva's Migraine Candidate TEV-48125 Positive in Phase III

                                                Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).

                                                  Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III

                                                  Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma.